Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2791)	11/11/2019 5:16:43 AM
From: Miljenko Zuanic	Respond to of 3557

<In my experience, biotech executives of companies whose drugs are being copied tend to overstate the manufacturing impediments. > Agree on that. Never hear directly from REGN any comment about aflibercept manufacturing. It is my perception, from its patent description, abs-description/production, and what is needed to have clean-production. REGN never have any issue from FDA in regards US-facility, recombinant protein need bit more muscle than regular Abs. However, anyone who looks on this issue should have open mind, and not take any statement from bios as granted. Botox is good example.